Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
Retatrutide
LY3437943, Eli Lilly Triple Agonist
A non-peptide, small-molecule GLP-1 receptor agonist developed by Eli Lilly. Unlike semaglutide and tirzepatide which are peptides requiring injection, orforglipron is a fully oral pill taken once daily with no fasting requirement. Phase 3 trials are underway, potentially making it the first truly convenient oral GLP-1 option.
An investigational triple-agonist peptide developed by Eli Lilly that targets GLP-1, GIP, and glucagon receptors simultaneously. Phase 3 clinical trials are underway, with early results showing unprecedented weight loss efficacy.
Activates GLP-1 receptors through a non-peptide chemical scaffold, producing the same downstream effects as injectable GLP-1 agonists — appetite suppression, insulin secretion, and slowed gastric emptying. The oral bioavailability is achieved through its small-molecule structure, unlike oral semaglutide (Rybelsus) which requires strict fasting protocols.
Activates three metabolic hormone receptors: GLP-1 (appetite suppression, insulin secretion), GIP (enhanced insulin response, fat metabolism), and glucagon (increased energy expenditure, fat oxidation). The triple mechanism may produce greater weight loss than dual agonists.
- Weight management (investigational)
- Type 2 diabetes (investigational)
- Metabolic health improvement
- Weight management (investigational)
- Type 2 diabetes (investigational)
- Metabolic syndrome (investigational)
- GI side effects (nausea, diarrhea, vomiting) — similar to injectable GLP-1s
- Still in Phase 3 trials — full safety profile not established
- Long-term cardiovascular outcomes data not yet available
- Not yet approved for any indication
- Still in clinical trials — full safety profile unknown
- GI side effects (nausea, diarrhea, vomiting) reported in trials
- Not yet approved for any indication
- Long-term effects unknown
Currently in Phase 3 clinical trials for obesity and type 2 diabetes. Phase 2 results showed ~14.7% weight loss at 36 weeks — comparable to injectable semaglutide. If approved, would be the first non-peptide oral GLP-1 agonist, removing the injection barrier for many patients. Potential approval 2026-2027.
Currently in Phase 3 clinical trials. Phase 2 results showed up to 24% body weight loss at 48 weeks. FDA approval timeline uncertain but potentially 2027-2028.
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.